PHARMA NEWS, MULTICHANNEL & CROSSCHANNEL MAKETING
315.6K views | +11 today
Follow

Biggest influencers in digital pharma in Q2 2020: The top individuals to follow #pharma #hcsmeufr #esante

From www.pharmaceutical-technology.com

GlobalData research has found the top digital pharma influencers based on their performance and engagement online in Q2 2020.

Lionel Reichardt / le Pharmageek:

Biggest influencers in digital pharma in Q2 2020: The top individuals to follow #pharma #hcsmeufr #esante

GlobalData research has found the top digital pharma influencers based on their performance and engagement online in Q2 2020.

No comment yet.

Otsuka backs GrayMatters' digital wearable tech for mental disorders -

From pharmaphorum.com

Japanese pharma group Otsuka has led a $10 million first-round financing of GrayMatters Health, an Israeli company developing
No comment yet.

Adieu les médicaments sans ordonnance : pourquoi « big pharma » se spécialise

From www.ouest-france.fr

Les laboratoires pharmaceutiques se délestent de leurs médicaments sans ordonnance. Ils se spécialisent, comme Servier dans l’oncologie.
No comment yet.

Un accès plus rapide aux médicaments, enjeu majeur des labos français pour 2022

From francais.medscape.com

La France veut devenir le leader européen du médicament et érige l’accès rapide aux traitements en priorité nationale. Telles sont les ambitions affichées par l’organisation patronale des entreprises du médicament (LEEM) à destination des candidats à la présidentielle.
No comment yet.

Laboratoires pharmaceutiques : une industrie, aujourd'hui encore, plus réactive que prospective

From www.latribune.fr

OPINION. Par nature, les acteurs du secteur sont plus enclins à suivre les évolutions technologiques et règlementaires que les tendances macro-sociétales. Par Frédéric Jallat, ESCP Business School
No comment yet.

» Neurosciences : Biogen annonce une nouvelle collaboration avec la start-up TheraPanacea 

From www.mypharma-editions.com

Biogen vient d'annoncer une nouvelle collaboration avec TheraPanacea, centrée sur plusieurs aires thérapeutiques en neurosciences et renforçant les liens existants entre les deux sociétés. L’objectif est de s’appuyer sur le machine learning (ML) et l’intelligence artificielle (IA) afin de tirer profit de l’imagerie médicale et d’autres sources de données cliniquement pertinentes
No comment yet.

J&J Medical Devices Partner with Microsoft to Expand Digital Surgery Solutions -

From hitconsultant.net

What You Should Know: Johnson & Johnson Medical Devices Companies (JJMDC) announced a strategic partnership with Microsoft to further enable our digital surgery solutions.  The Johnson & Johnson Medical Devices Companies (JJMDC) today announced that it will collaborate with Microsoft to further enable and expand JJMDC’s secure and compliant digital surgery ecosystem. The Microsoft Cloud will help JJMDC realize its vision of driving innovation ... Read More
No comment yet.

Coronavirus : comment le jackpot du vaccin redistribue les cartes des Big Pharma

From www.latribune.fr

LA DÉCENNIE COVID 2/5. Big Pharmas et biotechs, nouvelles stars des investisseurs, sont en première ligne alors que le SARS-COV-2 joue les prolongations. Mais entre le triomphe du grand champion Pfizer avec l'ARN-messager de BioNTech, la révélation Moderna et l'échec cuisant de Sanofi, le coronavirus a chamboulé le palmarès. S'il a donné un coup d'accélérateur à certaines innovations et certaines pratiques, a-t-il durablement bouleversé le paysage mondial ? Un avenir brillant est prédit aux champions de l'ARN-messager qui vont pouvoir financer d'autres innovations avec le cash du Covid. Décryptage.

Lire l'article complet sur : www.latribune.fr

No comment yet.

Médicaments : pourquoi Big Pharma veut sortir des produits grand public

From www.lemonde.fr

Le géant de l’agroalimentaire et des produits d’hygiène Unilever a proposé 60 milliards d’euros à l’industriel pharmaceutique GSK pour lui racheter sa branche de produits sans ordonnance.

Lire l'article complet sur : www.lemonde.fr

No comment yet.

L’innovation médicale, pilier du «nouveau» Johnson & Johnson

From www.lefigaro.fr

Joaquin Duato, qui a pris les rênes du laboratoire américain au 1er janvier, prévoit par ailleurs des acquisitions.

Lire l'article complet sur : www.lefigaro.fr

No comment yet.

Comment l’industrie pharma veut placer la santé au cœur des campagnes électorales

From www.usinenouvelle.com


Les Entreprises du médicament (Leem) réclament encore plus de soutien public à la fois pour l’industrialisation et la recherche, avec...-sante
No comment yet.

Sanofi et la pépite britannique Exscientia accélèrent la découverte de médicaments grâce à l'IA

From www.usine-digitale.fr


Sanofi signe un accord de collaboration avec la start-up britannique Exscientia pour découvrir de nouvelles molécules prometteuses dans la cancérologie et l'immunologie. Les travaux se reposeront sur la plateforme médicale, développée par la jeune pousse, qui utilise l'intelligence artificielle pour la découverte de médicaments, la rechercher translationnelle et la sélection des patients pour des essais cliniques. 
No comment yet.

Nouvel écosystème digital pour GSK France

From buzz-esante.fr

Le laboratoire GSK France enrichit son écosystème digital avec une nouvelle version de son site institutionnel pour répondre aux nouveaux usages et toucher plus efficacement l’ensemble de ses publics.
No comment yet.

CES 2022: Abbott Labs Keynote

From www.youtube.com

Live from #CES2022: Abbott shares how the technology revolution in health care empowers patients to improve lives.
No comment yet.

Abbott is working on ‘biowearables’ to measure glucose, lactate and ketones

From www.engadget.com

The devices will be able to continuously monitor your body's composition and help you take action..
Richard Platt's curator insight, January 9, 10:24 PM

Health tech company Abbott is working on “biowearable” devices to track certain elements of one’s body, with the idea that they’ll provide users with more insights about their general health and help them take action. The Lingo devices will measure glucose, ketones and lactate, and eventually they may be able to monitor alcohol levels.

The upcoming biowearables, which aren't intended for medical use, athletes are using a version of the device to help optimize their food intake for their training and competition. The company is planning to expand glucose monitoring use cases to help the public manage things like sleep, weight and energy levels.  The aim of the ketone biowearable is to offer continuous tracking of ketones so that wearers can see how quickly they get into ketosis. That's a state in which a body doesn't have enough carbohydrates to turn into energy and instead burns fat (and generates ketones). With the lactate wearable, Abbott's goal is to continuously measure lactate build up while working out. It says that can provide insights on athletic performance.  It'll be some time before Abbott can bring this tech to the consumer market. If and when the biowearables do arrive and they work as promised, they should help those interested in keeping close tabs on the condition of their body to do so.

Intelligence artificielle : Exscientia et Sanofi vont collaborer pour développer un portefeuille de médicaments de précision 

From www.mypharma-editions.com

Sanofi et Exscientia ont annoncé la conclusion d’un accord de licence et de collaboration de recherche novateur en vue du développement de jusqu’à 15 nouvelles petites molécules candidates en oncologie et immunologie, à l’aide de la plateforme d’intelligence artificielle (IA) entièrement intégrée d’Exscientia utilisant des échantillons biologiques de patients.
No comment yet.

Se former pour exercer dans la santé, un secteur en pleine transformation digitale #hcsmeufr #esante #mbadmbhealth

From www.blogdumoderateur.com

Le contexte actuel accélère la transformation digitale de la santé. Tour d’horizon des enjeux, des opportunités et des compétences nécessaires pour évoluer dans ce secteur.
No comment yet.

symplr announces plans to buy Conduent's Midas Health Analytics business for $340M

From www.mobihealthnews.com

symplr, a healthcare operations software developer, announced its plans to purchase Midas Health Analytics Solutions from Conduent for a whopping $340 million.

Midas will bring with it a data set that includes 100 million claims and over 30,000 indicators, as well as data from 800 hospitals. The service is aimed at guiding and creating tactical plans for healthcare customers.

symplr has a long history in the enterprise healthcare offerings space. Its services include data management, workforce management, finance management and regulatory compliance tools.

According to the announcement, the companies expect the deal to close in the first quarter of 2022.
No comment yet.

Medical education through Twitter? Pharma's digital strategy for healthcare providers

From medcitynews.com

At a time when a large portion of healthcare practitioner interactions have switched to digital, it’s clear that life science companies need to transform their approach to be much more collaborative in the way they work with healthcare professionals.

A new survey from Reuters Events in collaboration with Microsoft and Exeevo, Medical-commercial collaborating to win in the digital era, offers an inside look at the trends and challenges with which life science professionals have to contend, and how they are responding.

The survey of more than 1,000 senior professionals included pharma (46%) biotech (12%), medtech/device (4%) and consumer health companies (2%).
No comment yet.

Don't spam us, healthcare professionals plea, as they seek quality over quantity from pharma marketers

From www.fiercepharma.com

Reaching out to doctors with more digital content during the pandemic? Think quality over quantity, says a new Accenture study on pharma-healthcare professional interactions.

The good news? More than 8 in 10 (83%) of HCPs say the content they're getting from pharma companies is more relevant now than it was before COVID-19, and they likely have more time to read it. Three-quarters said they've seen fewer patients over the past year, and 61% said they have more available time than they did pre-pandemic.

But more clutter is hitting their inboxes, too, thanks to the pandemic-driven digital shift. Sixty-four percent of HCPs said they're getting too much digital content from pharma, while 65% felt at least one pharma company had “spammed” them during the pandemic.
No comment yet.

More digital therapeutics hit the market, pharma uses digital for real-world data in 2021

From www.mobihealthnews.com

Pharma companies continue to team up with startups and invest in AI for drug discovery.
No comment yet.

The Big Tech In Pharma Report: How Amazon, Microsoft, Apple, And Google Are Capitalizing On The Digital Transformation

From www.cbinsights.com

The pandemic has exposed challenges in the pharmaceutical industry, from drug discovery to clinical trials to supply chain. Here’s how Apple, Microsoft, Google, and Amazon are addressing them and working to establish permanent places for themselves in the space through product launches, partnerships, M&A deals, and more.  
No comment yet.

Biogen puts $15m into digital health alliance with TheraPanacea -

From pharmaphorum.com

Biogen has made a $15 million investment in digital health company TheraPanacea, which will go towards a project
No comment yet.

Owkin and Amgen Use AI to Improve Cardiovascular Risk Prediction

From pharmtechfocus.com

Owkin and Amgen announce results of three-year project to use artificial intelligence to more accurately predict cardiovascular risk
No comment yet.

Amgen, Owkin study shows cardiac-predicting AI outperforms traditional clinical methods

From www.fiercebiotech.com

Using information collected from more than 13,700 participants in an Amgen clinical trial, Owkin’s AI spotted which people had the highest risks of heart attacks or stroke.
No comment yet.